What does blinding accomplish in a trial?

• A. Revealing allocation to statisticians at the end.
• B. Binding to a single treatment arm.
• C. Revealing allocation to investigators at the end.
• D. Keeping treatment assignment unknown to participants and investigators.

Answer: (D)

Blinding aims to prevent bias by keeping the treatment assignment hidden from participants and investigators. When people don’t know who received which intervention, expectations cannot color reporting of symptoms, side effects, or outcomes, and researchers’ care or assessments can’t be unconsciously influenced by knowledge of the treatment. This reduces both performance bias (differences in care or behavior) and detection bias (biased outcome assessment). Blinding is especially important for subjective outcomes, but it helps protect the integrity of the entire trial by keeping comparisons fair. The purpose is to keep allocation unknown to those involved, whereas the other options describe revealing or binding someone to a specific arm, which would defeat the aim of blinding and introduce bias.